Research Article

Prevention of Postoperative Events following Reversal with Sugammadex or Neostigmine (the P-PERSoN Trial): Pilot Data Following Early Termination of a Prospective, Blinded, Randomised Trial

Benjamin Olesnicky, Matthew Doane, Clare Farrell, Greg Knoblanche, and Anthony Delaney

1Department of Anaesthesia, Royal North Shore Hospital, St Leonards, Australia
2The University of Sydney, Sydney, Australia
3Northern Sydney Anaesthetic Research Institute, St Leonards, Australia
4Department of Anaesthesia, Westmead Hospital, Sydney, Australia
5Department of Intensive Care Medicine, Royal North Shore Hospital, St Leonards, Australia
6Division of Critical Care, The George Institute for Global Health, Sydney, Australia

Correspondence should be addressed to Benjamin Olesnicky; benjamin.olesnicky@health.nsw.gov.au

Received 19 February 2022; Accepted 17 June 2022; Published 8 July 2022

Academic Editor: Fabrizio Monaco

Copyright ©2022 Benjamin Olesnicky et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Residual paralysis following anaesthesia is common and can lead to postoperative morbidity. While sugammadex has been shown to be effective in minimising residual paralysis, uncertainty exists as to whether its use reduces any associated morbidity. We designed this trial to determine if the use of sugammadex for the reversal of intraoperative aminosteroid neuromuscular blockade results in improvements in postoperative pulmonary complications, complications in the recovery unit, postoperative nausea and vomiting, and patient satisfaction, when compared to reversal with neostigmine. Methods. A prospective, double-blind, randomised controlled trial in adult patients admitted for surgical operations at two Australian hospitals between December 2018 and March 2019 was performed comparing the reversal of neuromuscular paralysis using sugammadex 2 mg/kg versus neostigmine 50 mcg/kg. Statistical analysis of continuous data was performed using two tailed t-tests, with categorical and ordinal data being assessed by chi-squared analysis. Results. The trial was terminated due to a combination of resource constraints and the 2019 novel coronavirus disease (COVID-19) pandemic. Of 51 patients screened, 33 were eligible for participation and 30 subsequently recruited and randomised. All patients received the intended treatment allocated. Data for the primary outcome was obtained in all patients. There was no difference in the rates of postoperative pulmonary complications between the sugammadex and neostigmine groups (0% (0/19) vs 9% (1/11) RR 5.0 (95% CI 0.22–113) p = 0.37. There was no difference in any of the secondary outcomes between the groups. Conclusions. The P-PERSoN trial showed no difference in postoperative pulmonary complications between sugammadex and neostigmine based reversal of aminosteroid neuromuscular block, but was underpowered to show any difference due to early trial termination. The randomisation and data collection was feasible. We support the need for an adequately resourced and funded randomised controlled trial to address this important clinical question.
1. Background

The practice of modern anaesthesia involves the use of muscle relaxants to provide muscle paralysis to enable surgical access and to allow effective mechanical ventilation. At the end of surgery, these muscle relaxants need to either be cleared and no longer be active, or be reversed, as significant residual relaxant activity will lead to residual paralysis. Residual paralysis is associated with increased patient morbidity. [1–5]

Sugammadex was introduced into clinical practice in Australia in 2009 and was specifically designed to reverse rocuronium by encapsulating it irreversibly and blocking its activity at the neuromuscular end plate [6]. Previous research has explored the effectiveness of sugammadex to prevent residual paralysis, consistently showing a reduction in the incidence of residual paralysis with sugammadex when compared with neostigmine [5, 7–9].

While sugammadex is shown to consistently reduce the incidence of residual paralysis, studies of the ability of sugammadex to prevent postoperative morbidity provide conflicting evidence. A single published randomised prospective study showed that, while sugammadex was associated with a significant reduction in residual paralysis, this did not lead to a reduction in postoperative pulmonary complications (PPCs) [10].

In addition to this, there have been three recent large trials utilising large data sets, which produced conflicting results. These studies showed that the use of sugammadex either was [11] or was not associated with a reduction in PPCs [12, 13].

These conflicting results provide equipoise as to the clinical effect of sugammadex on postoperative pulmonary complications in modern anaesthetic practice and justify the need for a randomised controlled trial to determine whether the use of sugammadex improves patient outcomes.

P-PERSoN was designed as a prospective multicentre, double-blinded, randomised controlled trial to evaluate if the use of sugammadex improves patient outcomes.

2. Methods

2.1. Trial Design. Across two centres (both a large quaternary public hospital and private hospital setting), adults admitted for surgical operations requiring muscle paralysis were enrolled in a prospective, double-blind, randomised controlled trial comparing specific outcomes following reversal with sugammadex or neostigmine. The study was approved by the Northern Sydney Local Health District Human Research Ethics Committee (RESP/16/289) and the North Shore Private Hospital Ethics Committee [2017-001].

The trial was registered at the Australian New Zealand Clinical Trials Registry (www.anzctr.org.au) # ACTRN1261600063415 (21/01/2016) and the U.S. National Library of Medicine (www.ClinicalTrials.gov) # NCT02825576 (07/07/2016). The trial was compliant with the Australian National Health and Medical Research Council (NHMRC) statement on ethical conduct in human research (2007) [14] and the note for guidance on good clinical practice (CPMP/ICH-135/95) [15]. A preprint of this study was submitted prior to formal publication [16].

2.2. Participants. Screening for eligible patients was conducted by examining operating theatre and preadmission clinic schedules for each day. Inclusion criteria were: patients over 18 years of age, planned to undergo noncardiac surgery with an expected operative time of >2 hours, use of endotracheal intubation, and an expected hospital length of stay greater than one night. These criteria were designed to preferentially select patients who would likely be at intermediate or high risk for PPCs [17].

Exclusion criteria were: patients previously recruited, patient weight >200 kg, patients planned to remain intubated postoperatively, and those with known hypersensitivity reactions or contraindications to any of the study drugs.

Patient recruitment occurred during a preoperative consultation, either in a preadmission clinic or on a hospital ward, prior to their transfer to the operating theatre.

2.3. Interventions. Patients were randomly assigned to one of two groups; the sugammadex group or the neostigmine group. At the end of surgery, the participant received a blinded reversal dose via a 10 ml syringe with administration of 1 mL/10 kg of the blinded solution. The solution was standardised to contain the protocol’s reversal dose that would equate to either 2 mg/kg of sugammadex or 50 mcg/kg neostigmine with 10 mcg/kg glycopyrrolate.

The study protocol required the use of intraoperative neuromuscular twitch (NMT) monitoring to ensure the return of a train-of-four count (TOFC) greater than or equal to 2 prior to reversal and restricted the use of neuromuscular blockers to rocuronium or vecuronium, at the choice of the individual anaesthetist.

There were no restrictions on the mode of anaesthesia, analgesia (including opioid use), use of postoperative nausea and vomiting (PONV) prophylaxis, or timing of neuromuscular blockade reversal.

2.4. Randomisation. Patients were allocated to treatment group via a computer-based simple randomisation software (https://randomizer.org). Group allocations were placed in a sealed opaque envelope by a research team member who was not involved in patient treatment or follow up. Prior to reversal, the treating anaesthetist recruited a member of the hospital clinical staff to open the next available randomisation envelope, draw up the allocated reversal agent based on the enclosed instructions, and deliver this to the treating anaesthetist. This individual was then not involved in further management of the trial patient.

2.5. Blinding. The patient, treating anaesthetist, all care providers, and research personnel assessing patient outcomes were all blinded to the patient’s treatment allocation.
2.6. Outcomes. The primary outcome was the incidence of PPCs (as defined by the European Perioperative Clinical Outcome (EPCO) statement [18] in the first three days postoperatively (Table 1)).

Secondary outcomes were: patient reported quality of recovery at day 1 and 30 utilising the QoR-15 [19], the incidence of PONV, and the incidence of a defined set of airway events in the postanaesthetic care unit (PACU). In addition to the quality-of-recovery-15 score (QoR-15) at day 30, patients were also asked if they had also received either antibiotics or bronchodilators to treat a chest infection (or if previously on bronchodilators, whether they had increased their usage or dose) in the interim. The hospital discharge summary was reviewed to identify the diagnosis of a respiratory infection or associated complications and to calculate hospital length of stay.

Table 1 outlines the EPCO definition, ARISCAT, and Apfel scores, PACU Airway Events and the PONV scoring systems used.

2.7. Sample Size. We planned to study 972 based on a power analysis, but as this study was terminated early, the data for 30 patients is presented as pilot data.

2.8. Statistical Analysis. The presence of a PPC, and the presence of PACU events were assessed as categorical variables, the QoR-15 score and hospital stay were assessed as continuous variables, and the PONV score was assessed as an ordinal variable. Continuous variables were assessed with two-tailed t-tests, categorical and ordinal data were assessed by the chi-squared analysis of contingency tables (or Fisher’s exact test when \( n < 5 \) in any outcome).

3. Results

3.1. Participant Flow. The trial commenced in December 2018 and was subsequently paused in March 2019 due to the abrupt resignation of research personnel needed to support the trial. This was followed by a prolonged approval and recruitment process to replace them. The recruitment process was completed in January 2020, and while planning to restart, the COVID-19 epidemic occurred. Due to the delay in restarting and absence of funding, the trial investigators made the decision to terminate the trial early and the results were analysed to inform future large-scale randomised controlled trials (RCTs) comparing similar outcomes with the use of sugammadex or neostigmine.

A total of 51 patients were screened for eligibility. Of those 33 (65% of screened patients) met criteria and were enrolled. There were three patients who had their surgery following study termination, leaving 30 patients to achieve randomisation. The study drug was successfully delivered to 100% of randomised patients. All patients had primary outcome data collected, with a 97% data completion rate for in-hospital data and a 93% completion rate for 30-day data collection (Figure 1). The CONSORT checklist for this trial is available in the Supplementary Material (available (here)).

PACU stands for postanaesthesia care unit and ICU is the intensive care unit. Baseline demographics and clinical characteristics were similar in both groups (Table 2).

All randomised patients received the study drug as per their assigned group. There was one violation in the sugammadex group, where a patient received the assigned reversal agent despite having only one twitch on NMT monitoring (reported as being suitable for extubation on clinical grounds by the treating anaesthetist). One patient had no PACU data, as they unexpectedly remained intubated and subsequently were transferred directly to the intensive care unit (ICU) (neostigmine group). Two patients in the sugammadex group were lost to follow up for 30-day data collection.

Due to the early termination and low numbers, there were no interim analyses performed and subgroup analysis was not performed. While the number of participants recruited for participation does not meet those needed to power the study’s analysis, we present their results below.

3.2. Primary Outcome–Postoperative Pulmonary Complications. One patient in the neostigmine group, and no patients in the sugammadex group, had a documented PPC (9% (95% CI 0–41%): vs 0% (0–17%)). RR 5.0 (95% CI 0.22–113) \( p = 0.37 \).

3.3. Quality of Recovery. The neostigmine group reported a mean QoR-15 score (95% CI) of 87 (60–104) at day 1, and 133 (120–146) at day 30, the mean (95% CI) QoR score in the sugammadex group was 102 (88–116) \( p = 0.21 \) and 129 (117–142) \( p = 0.61 \), respectively.

3.4. Postoperative Nausea and Vomiting. Postoperative nausea and vomiting was reported in one subject (1/10) in the neostigmine group vs three patients in the sugammadex group (3/19) RR 1.6 (95% CI 0.18–13.3) \( p = 0.99 \).

3.5. Complications in the Postoperative Anaesthesia Care Unit. There was one incidence of desaturation to <90% in both the sugammadex and neostigmine groups (5.3% vs 10% \( p = 0.99 \)). There were no other airway complications detected in either group. Two patients in each of the groups required a review by an anaesthetist (sugammadex group 10.6% vs neostigmine group 20% \( p = 0.59 \)). In the sugammadex group, one review was for bradycardia, while the second was for shortness of breath. Subsequent reviews for participants in the neostigmine group were for a new onset wheeze with desaturation in one patient, and for uncontrolled pain in a second patient.

3.6. Hospital Stay. The hospital length of stay was similar between both groups. (Group S: 4.2 (2.8–5.6) days, Group N: 5.6 (2.2–9.0) days, \( p = 0.44 \)).
Table 1: Definitions used for outcome measurements and risk stratification.

| European perioperative clinical outcome (EPCO) definitions of postoperative pulmonary complications [18] |
|-------------------------------------------------------------------------------------------------|
| **Respiratory infection** | Patient has received antibiotics for suspected respiratory infection and met one or more of the following criteria: new or changed sputum, new or changed lung opacities, fever, white blood cell count > 12 × 10^9/litre |
| **Respiratory failure** | Postoperative PaO2 < 60 mmHg on room air, PaO2 : FiO2 ratio < 300 mmHg, or arterial oxyhaemoglobin saturation measured with pulse oximetry < 90% and needing oxygen therapy |
| **Pleural effusion** | Chest radiograph showing blunting of costophrenic angle, loss of sharp silhouette of ipsilateral hemidiaphragm in upright position, evidence of displacement of adjacent anatomical structures, or (in supine position) hazy opacity in one hemithorax with preserved vascular shadows |
| **Atelectasis** | Lung opacification with shift of mediastinum, hilum, or hemidiaphragm towards affected area, and compensatory over-inflation in adjacent nonatelectatic lung |
| **Pneumothorax** | Air in pleural space with no vascular bed surrounding visceral pleura |

Assess respiratory risk in surgical patients in catalonia (ARISCAT) score for risk prediction of postoperative pulmonary complications [17]

| Risk factor | Score |
|-------------|-------|
| Age 51–80   | 3     |
| Age > 80    | 16    |
| Preoperative SpO2 91–95% | 8 |
| Preoperative SpO2 ≤ 90% | 24 |
| Respiratory infection in past 1 month | 17 |
| Preoperative haemoglobin < 10 gm/dl | 11 |
| Upper abdominal incision | 15 |
| Intrathoracic incision | 24 |
| Surgery duration 2-3 hours | 16 |
| Surgery duration > 3 hours | 23 |
| Emergency procedure | 8 |

Total score-low risk: <26, intermediate risk: 26–44, high risk: ≥45

Apfel score for risk prediction of PONV [20]

| Total score and risk stratification |
|-----------------------------------|
| 0 | Minimal risk |
| 1 | Low risk |
| 2 | Intermediate risk |
| 3 | High risk |
| 4 | Very high risk |

Definitions of postoperative care unit events

PACU events
1. Any desaturation to SpO2 < 90%
2. Need for manual airway support
3. Need for oropharyngeal or nasopharyngeal airway
4. Need for reintubation in PACU
5. Need for anaesthetist to review the patient
6. Unplanned ICU admission
7. No PACU admission
PONV score
1. No PONV
2. PONV responsive to antiemetics
3. PONV unresponsive to antiemetics

PaO2, partial pressure of arterial oxygen; FiO2, fraction of inspired oxygen; SpO2, peripheral capillary oxygen saturation; PONV, postoperative nausea and vomiting; PACU, post anaesthesia care unit; ICU, intensive care unit.
3.7. Postoperative Follow Up. One patient was found to have received antibiotics for a chest infection on day 30 in the sugammadex group, with no patients in the neostigmine group reporting the need for antibiotics and no patients in either group reporting new or increased bronchodilator therapy in the 30 days postoperatively. Table 3 provides a summary of all outcome data collected.

4. Discussion

This randomised controlled trial was constructed to assess neuromuscular blockade reversal with sugammadex compared to neostigmine in patients who were at intermediate to high risk of PPC. The trial was ceased early due to resource constraints and COVID-19. In the small numbers that were recruited there was no difference detected in the rates of postoperative pulmonary complications following reversal with sugammadex when compared with reversal with neostigmine. There was also no difference found between groups in terms of patient quality of recovery, as measured by the QoR-15 score, postoperative nausea and vomiting, a composite of PACU events and hospital length of stay, and the need for chest infection treatment in the first 30 days postoperatively. Given the small sample size before trial termination, there was no ability to assess for clinically meaningful or statistically significant differences in outcomes, and as such, the outcomes of this study cannot be directly translated into clinical care.

Despite these limitations, the experience of designing and initiating this trial has led to a number of practical recommendations for future attempts at similar endeavours. Firstly, a more clinically relevant patient-centred primary outcome would be recommended. Days Alive and at Home to Day 30 (DAH30), is a validated, patient-centred outcome that is associated with surgical complexity, in-hospital complications, and longer-term outcomes, which can also be easily linked to economic outcomes [21]. Additionally, good published data exists in a variety of surgical populations of mean and variability
for DAH$_{30}$ to provide for power analysis [22]. Future studies should also consider assessing a return to normal function, including normal levels of work/study, to further assess any social and economic implications of clinical outcomes/impacts.

Finally, using the QOR-15 at 30 days as a measure of quality of recovery needs an adaptation for out of hospital use, as one of the included questions is worded to enquire about “support from hospital doctors and nurses”, which is not relevant after discharge. A modified QoR-15 questionnaire to assess “receiving support from healthcare services, if you needed it” could address this incompatibility, or the use of an alternative validated quality of life metric.

We have reported the study according to randomised study standards as recommended by the Consolidated Standards of Reporting Trials (CONSORT) group [23].

5. Conclusions

We were not able to discern whether sugammadex compared to neostigmine was associated with a reduced rate of

---

**Table 2: Demographic characteristics of study participants.**

|                | Sugammadex | Neostigmine |
|----------------|------------|-------------|
| Age (years) mean (SD) | 57±/−7 | 58±/−7 |
| Female sex (n/total) | 68% (13/19) | 45% (5/11) |
| ASA class (n/total) | 68% (13/19) | 55% (6/11) |
| 1               | 11% (2/19) | 9% (1/11) |
| 2               | 68% (13/19) | 55% (6/11) |
| 3               | 21% (4/19) | 36% (4/11) |
| 4               | 0% (0/19) | 0% (0/11) |
| Height (cm)     | 165+/−4 | 171+/−6 |
| Weight (kg)     | 78+/−8 | 81+/−18 |
| BMI             | 28+/−2 | 28+/−5 |
| Current smoker (n/total) | 5% (1/19) | 9% (1/11) |
| Duration of surgery (min) | 197+/−25 | 204+/−51 |
| Relaxant used (n/total) | 21% (4/19) | 45% (5/11) |
| Rocuronium      | 12% (15/19) | 55% (6/11) |
| Vecuronium      | 79% (15/19) | 55% (6/11) |
| PONV prophylaxis (n/total) | None | 18% (2/11) |
| Dexamethasone   | 26% (5/19) | 18% (2/11) |
| Ondansetron     | 11% (2/19) | 27% (3/11) |
| Dexamethasone/ondansetron | 58% (11/19) | 36% (4/11) |
| Dexamethasone/droperidol | 5% (1/19) | 0/11 (0/11) |
| ARISCAT risk score (n/total) | Low | 33% (6/18)* |
| Intermediate    | 67% (12/18)* | 45% (5/11) |
| High            | 0% (0/18)* | 27% (3/11) |
| Apfel risk score (n/total) | Minimal | 0% (0/19) | 0% (0/11) |
| Low             | 16% (3/19) | 36% (4/11) |
| Intermediate    | 74% (14/19) | 64% (7/11) |
| High            | 11% (2/19) | 0% (0/11) |
| Very high       | 0% (0/19) | 0% (0/11) |

*one patient had no preoperative Hb, therefore could not calculate ARISCAT score. SD, standard deviation; ASA, American society of anesthesiologists; ARISCAT, assess respiratory risk in surgical patients in Catalonia; BMI, body-mass index; PONV, postoperative nausea and vomiting.

**Table 3: Outcome data.**

| Outcome                                      | Sugammadex   | Neostigmine   | p value |
|----------------------------------------------|--------------|---------------|---------|
| Postoperative pulmonary complication         | 0 (0–17)%    | 9 (0–41)%     | 0.37    |
| PONV score > 1                               | 16 (3–40)%   | 10 (0–44)%    | 0.99    |
| Events in PACU (%)                           | 16 (3–40)%   | 27 (6–60)%    | 0.59    |
| QOR-15 Day 1                                 | 102 (88–116) | 87 (60–104)   | 0.21    |
| QoR-15 Day-30                                | 129 (117–142)| 133 (120–146) | 0.61    |
| Need for postoperative antibiotics to day 30 | 6 (0–29)%    | 0 (0–28)%     | 0.99    |
| Need for new or increased bronchodilators to day 30 | 0 (0–19)% | 0 (0–28)% | 0.99 |
| Hospital discharge summary diagnosis of respiratory infection | 0 (0–18)% | 0 (0–28)% | 0.99 |
| Hospital length of stay (days)               | 4.2 (2.8–5.6)| 5.6 (2.2–9.0) | 0.44    |

PONV, postoperative nausea and vomiting, QoR-15, quality of recovery-15 score, PACU, postanaesthetic care unit). data presented as n (95% CI).
postoperative pulmonary complications. Future research to definitively address this question is needed and appears feasible with a well-designed and adequately funded study.

**Abbreviations**

ARISCAT: Assess respiratory risk in surgical patients in Catalonia

ASA: American society of anesthesiologists

BMI: Body mass index

CONSORT: Consolidated standards of reporting trials

COVID: Coronavirus disease

DAH30: Days alive and at home to day 30

DSMC: Data and safety monitoring committee

EPCO: European perioperative clinical outcome

ICU: Intensive care unit

NHMRC: National health and medical research council

NMT: Neuromuscular twitch

NNT: Number needed to treat

PACU: Postanaesthetic care unit

PONV: postoperative nausea and vomiting

POPULAR: Postanaesthesia pulmonary complications after use of muscle relaxants

PPC: Postoperative pulmonary complication

QoR-15: Quality-of-recovery-15 score

RCT: Randomised controlled trial

STRONGER: Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications

TIVA: Total intravenous anaesthesia

TOFC: Train-of-four count.

**Data Availability**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Ethical Approval**

The study was approved by the Northern Sydney Local Health District Human Research Ethics Committee (RESP/16/289) and the North Shore Private Hospital Ethics Committee [2017-001]. Informed consent was obtained from all participants.

**Conflicts of Interest**

The authors declare that there are no conflicts of interest.

**Authors’ Contributions**

BO made substantial contributions to the conception and design of the work; the acquisition, analysis and interpretation of data; and drafted the work or substantively revised it. MD made substantial contributions to the design of the work; the acquisition, analysis, and interpretation of data; and drafted the work or substantively revised it. CF made substantial contributions to the conception and design of the work and drafted the work or substantively revised it. GK made substantial contributions to the conception and design of the work and drafted the work or substantively revised it. AD made substantial contributions to the conception and design of the work and either drafted the work or substantively revised it. All authors read and approved the final manuscript.

**Acknowledgments**

The authors would like to thank the following team members for their contributions to this trial: participating centres, Royal North Shore Hospital and North Shore Private Hospital; research coordinator, Ms Courtney Player; and the Data Safety and Management Committee, Professor Peter Kam and Dr Ross Wallace.

**Supplementary Materials**

Protocol 2.1 – Full Protocol of trial. CONSORT 2010 Checklist P-PERSoN–Copy of CONSORT checklist. Supplementary Materials. (Supplementary Materials)

**References**

[1] U. Bissinger, F. Schimek, and G. Lenz, “Postoperative residual paralysis and respiratory status: a comparative study of pancuronium and vecuronium,” *Physiological Research*, vol. 49, no. 4, pp. 455–462, 2000.

[2] G. S. Murphy, J. W. Szokol, J. H. Marymont, S. B. Greenberg, M. J. Avram, and J. S. Vender, “Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit,” *Anesthesia & Analgesia*, vol. 107, no. 1, pp. 130–137, 2008.

[3] G. S. Murphy, J. W. Szokol, M. Franklin, J. H. Marymont, M. J. Avram, and J. S. Vender, “Postanesthesia care unit recovery times and neuromuscular blocking drugs: a prospective study of orthopedic surgical patients randomized to receive pancuronium or rocuronium,” *Anesthesia & Analgesia*, vol. 98, no. 1, pp. 193–200, 2004.

[4] H. Berg, J. Roed, J. Vibly-Mogensen et al., “Residual neuromuscular block is a risk factor for postoperative pulmonary complications. a prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium,” *Acta Anaesthesiologica Scandinavica*, vol. 41, no. 9, pp. 1095–1103, 1997.

[5] G. V. Cammu, V. Smet, K. de Jongh, and D. Vandeput, “A prospective, observational study comparing postoperative residual curarisation and early adverse respiratory events in patients reversed with neostigmine or sugammadex or after apparent spontaneous recovery,” *Anaesthesia & Intensive Care*, vol. 40, no. 6, pp. 999–1006, 2012.

[6] L. H. D. J. Booij, “Cyclodextrins and the emergence of sugammadex,” *Anaesthesia*, vol. 64, pp. 31–37, 2009.

[7] T. Ledowski, S. Hillyard, B. O’Dea, R. Archer, F. Vilas-Boas, and B. Kyle, “Introduction of sugammadex as standard reversal agent: impact on the incidence of residual neuromuscular blockade and postoperative patient outcome,” *Indian Journal of Anaesthesia*, vol. 57, no. 1, p. 46, 2013.

[8] B. Brueckmann, N. Sasaki, P. Grobara et al., “Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study,” *British Journal of Anaesthesia*, vol. 115, no. 5, pp. 743–751, 2015.
[9] Y. Kotake, R. Ochiai, T. Suzuki et al., "Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block," Anesthesia & Analgesia, vol. 117, no. 2, pp. 345–351, 2013.

[10] B. M. Togioka, D. Yanez, M. F. Aziz, J. R. Higgins, P. Tekkali, and M. M. Treggiari, "Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery," British Journal of Anaesthesia, vol. 124, no. 5, pp. 553–561, 2020.

[11] S. Kheterpal, M. T. Vaughn, T. Z. Dubovoy et al., "Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (stronger): a multicenter matched cohort analysis," Anesthesiology, vol. 132, no. 6, pp. 1371–1381, 2020.

[12] E. Kirmeyer, L. I. Eriksson, H. Lewald et al., "Post-anaesthesia pulmonary complications after use of muscle relaxants (popular): a multicentre, prospective observational study," Lancet Respiratory Medicine, vol. 7, no. 2, pp. 129–140, 2019.

[13] G. Li, R. E. Freundlich, R. K. Gupta et al., "Postoperative pulmonary complications’ association with sugammadex versus neostigmine: a retrospective registry analysis," Anesthesiology, vol. 134, no. 6, pp. 862–873, 2021.

[14] The National Health and Medical Research Council tAR-CaUA, National Statement on Ethical Conduct in Human Research, Commonwealth of Australia bank, Sydney, Australia, 2007.

[15] (ICH) ICHTrPfHU, "Integrated addendum to ICH E6(R1): guideline for good clinical practice," https://ichgcp.net/2016.

[16] B. L. D. M. Olesnicky, C. Farrell, G. Knoblanche, and A. Delaney, "Prevention of postoperative events following reversal with sugammadex or neostigmine (the P-PERSoN trial) – pilot data following early termination of a prospective, blinded, randomised trial," https://wwwresearchsquarecom/article/rs-960365/v1.

[17] V. Mazo, S. Sabate, J. Canet et al., "Prospective external validation of a predictive score for postoperative pulmonary complications," Anesthesiology, vol. 121, no. 2, pp. 219–231, 2014.

[18] I. Jammer, N. Wickboldt, M. Sander et al., "Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: European perioperative clinical outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative outcome measures," European Journal of Anaesthesiology, vol. 32, no. 2, pp. 88–105, 2015.

[19] P. A. Stark, P. S. Myles, and J. A. Burke, "Development and psychometric evaluation of a postoperative quality of recovery score: the QoR-15," Anesthesiology, vol. 118, no. 6, pp. 1332–1340, 2013.

[20] C. C. Apfel, E. Laara, M. Koivuranta, C. A. Greim, and N. Roewer, "A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers," Anesthesiology, vol. 91, no. 3, p. 693, 1999.

[21] A. Jerath, P. C. Austin, and D. N. Wijeysundera, "Days alive and out of hospital: validation of a patient-centered outcome for perioperative medicine," Anesthesiology, vol. 131, no. 1, pp. 84–93, 2019.

[22] P. S. Myles, M. A. Shulman, S. Heritier et al., “Validation of days at home as an outcome measure after surgery: a prospective cohort study in Australia,” BMJ Open, vol. 7, no. 8, Article ID e015828, 2017.

[23] K. F. Schulz, D. G. Altman, D. Moher, and C. Group, "CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials," BMJ, vol. 340, p. c332, 2010.